YMI- 1.69. ASH will definitely generate interest. From what i understand and as you explained before, Anaemia and transfusion dependance is the KEY which separates YMI from other JAK inhibitors. This will be value driver for the company going forward. This will make company attractive for partnership with pharma gaint or takeover in medium term. I am very comfortable holding this below $2.5 any day.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.